BMAC – Biopharmaceutical Manufacturer's Advisory Council
An initiative by leading Biopharmaceutical companies in the world to establish Singapore as the country of choice for global biomedical sciences manufacturing.
AstraZeneca plans to hire over 800 employees in Singapore for highly skilled roles ranging from engineering, quality, technical services to global supply chain, as it begins construction of its manufacturing facility for antibody drug conjugates (ADCs), treatments that deliver highly potent cancer-killing agents directly to cancer cells through targeted antibodies.
Sanofi announced the inauguration of its state-of-the-art manufacturing facility, Modulus, in Singapore, marking a significant milestone in its commitment to delivering innovative healthcare solutions globally. This next-generation facility, located in Tuas Biomedical Park, is highly digitalised and low-carbon, representing a new era in sustainable biopharmaceutical manufacturing. Modulus leverages a ‘industry first’ modular concept that enables flexible manufacturing capabilities to produce next generation vaccines and biological medicines. The inauguration was witnessed by Mr Ong Ye Kung, Singapore’s Minister for Health.
Pfizer Inc. today announced the extension of the company’s highly automated Active Pharmaceutical Ingredient (API) manufacturing facility in Tuas Biomedical Park, Singapore. The official opening ceremony was graced by Singapore’s Deputy Prime Minister and Minister for Trade and Industry Mr. Gan Kim Yong.
Pfizer Inc. today announced the extension of the company’s highly automated Active Pharmaceutical Ingredient (API) manufacturing facility in Tuas Biomedical Park, Singapore. The official opening ceremony was graced by Singapore’s Deputy Prime Minister and Minister for Trade and Industry Mr. Gan Kim Yong.
GSK has today announced it has signed a 10-year energy deal with Sembcorp, covering the electricity demand for all three of GSK’s global manufacturing sites in Singapore. This means that from 1 January 2025, all of GSK’s manufacturing operations in Singapore will be covered by renewable energy certificates from Sembcorp’s solar projects in Singapore and the 3% already being generated by GSK’s on-site solar panels.
WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, today announced the groundbreaking of its new R&D and manufacturing site in Singapore.
Every parent of a newborn knows the toll of sleepless nights, and Mr Lam Wain Sion is no exception. However, thanks to the 16 weeks of paid parental leave he was entitled to as an employee of Swiss pharmaceutical company Novartis, he could help his wife with diaper changes and night feeds without worrying about turning up at work sleep-deprived.
When he was a child, Mr Shaji Alias watched a family member struggle with asthma and saw the difference that one of GSK’s medicines made. Little did he know that he would one day end up working for the global biopharma company.
Every parent of a newborn knows the toll of sleepless nights, and Mr Lam Wain Sion is no exception. However, thanks to the 16 weeks of paid parental leave he was entitled to as an employee of Swiss pharmaceutical company Novartis, he could help his wife with diaper changes and night feeds without worrying about turning up at work sleep-deprived.
WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has broken ground on its new 13.5-hectare CRDMO center in Tuas Biomedical Park, Singapore. The center will provide integrated biologics research, development and manufacturing services.